As my speculative portfolio crumbles in light of COVID-19, I am periodically checking in on those candidates which I retain to evaluate their rebound prospects. This is my evaluation of Acadia (ACAD).
NUPLAZID revenues look to remain strong as 2020 unfolds, however the COVID-19 virus may scramble the picture to some extent
Acadia's sole FDA-approved therapy, NUPLAZID in the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis [PDP] was approved in 2016. With the exception of a brief lull traceable to a muckraking CNN article during Q2 2018, Acadia's NUPLAZID revenues